Beijing Strong Biotechnologies, Inc. (300406.SZ)
CNY 15.07
(-1.76%)
CNY 15.07
(-1.76%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 523.74 Million CNY | 34.6% |
| 2022 | 389.09 Million CNY | -4.08% |
| 2021 | 405.65 Million CNY | 261.29% |
| 2020 | 112.27 Million CNY | -66.15% |
| 2019 | 331.64 Million CNY | 10.3% |
| 2018 | 300.66 Million CNY | 10.07% |
| 2017 | 273.15 Million CNY | 0.55% |
| 2016 | 271.64 Million CNY | 10.86% |
| 2015 | 245.04 Million CNY | 16.33% |
| 2014 | 210.64 Million CNY | 16.61% |
| 2013 | 180.63 Million CNY | 31.84% |
| 2012 | 137 Million CNY | 35.95% |
| 2011 | 100.78 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 120.64 Million CNY | -20.85% |
| 2024 Q3 | 123.01 Million CNY | -5.18% |
| 2024 Q2 | 129.72 Million CNY | 7.52% |
| 2023 Q3 | 129.74 Million CNY | -0.61% |
| 2023 Q4 | 152.42 Million CNY | 17.48% |
| 2023 FY | 523.74 Million CNY | 34.6% |
| 2023 Q1 | 111.02 Million CNY | -7.36% |
| 2023 Q2 | 130.54 Million CNY | 17.59% |
| 2022 FY | 389.09 Million CNY | -4.08% |
| 2022 Q4 | 119.84 Million CNY | 12.59% |
| 2022 Q3 | 106.43 Million CNY | 64.41% |
| 2022 Q2 | 64.73 Million CNY | -34.01% |
| 2022 Q1 | 98.11 Million CNY | 3.36% |
| 2021 Q1 | 112.16 Million CNY | 355.21% |
| 2021 Q2 | 109.02 Million CNY | -2.8% |
| 2021 FY | 405.65 Million CNY | 261.29% |
| 2021 Q3 | 89.55 Million CNY | -17.86% |
| 2021 Q4 | 94.91 Million CNY | 5.99% |
| 2020 Q4 | 24.63 Million CNY | -53.93% |
| 2020 Q3 | 53.48 Million CNY | 149.76% |
| 2020 Q2 | 21.41 Million CNY | 68.11% |
| 2020 FY | 112.27 Million CNY | -66.15% |
| 2020 Q1 | 12.73 Million CNY | -88.82% |
| 2019 Q2 | 71.52 Million CNY | 18.74% |
| 2019 FY | 331.64 Million CNY | 10.3% |
| 2019 Q4 | 113.96 Million CNY | 32.65% |
| 2019 Q3 | 85.91 Million CNY | 20.11% |
| 2019 Q1 | 60.23 Million CNY | -43.09% |
| 2018 Q2 | 56.62 Million CNY | -2.21% |
| 2018 Q3 | 80.28 Million CNY | 41.78% |
| 2018 FY | 300.66 Million CNY | 10.07% |
| 2018 Q1 | 57.9 Million CNY | -36.59% |
| 2018 Q4 | 105.84 Million CNY | 31.83% |
| 2017 Q3 | 73.1 Million CNY | 27.88% |
| 2017 Q4 | 91.32 Million CNY | 24.92% |
| 2017 FY | 273.15 Million CNY | 0.55% |
| 2017 Q1 | 51.55 Million CNY | -38.05% |
| 2017 Q2 | 57.16 Million CNY | 10.89% |
| 2016 Q1 | 64.08 Million CNY | -17.79% |
| 2016 Q2 | 57.04 Million CNY | -10.99% |
| 2016 FY | 271.64 Million CNY | 10.86% |
| 2016 Q4 | 83.21 Million CNY | 23.66% |
| 2016 Q3 | 67.29 Million CNY | 17.97% |
| 2015 Q2 | 52.18 Million CNY | -4.34% |
| 2015 Q1 | 54.55 Million CNY | -0.57% |
| 2015 Q4 | 77.95 Million CNY | 29.18% |
| 2015 FY | 245.04 Million CNY | 16.33% |
| 2015 Q3 | 60.35 Million CNY | 15.66% |
| 2014 Q4 | 54.86 Million CNY | -3.13% |
| 2014 Q2 | 51.72 Million CNY | 9.1% |
| 2014 Q1 | 47.41 Million CNY | -4.34% |
| 2014 FY | 210.64 Million CNY | 16.61% |
| 2014 Q3 | 56.63 Million CNY | 9.5% |
| 2013 FY | 180.63 Million CNY | 31.84% |
| 2013 Q4 | 49.56 Million CNY | 9.84% |
| 2013 Q3 | 45.12 Million CNY | 0.0% |
| 2012 FY | 137 Million CNY | 35.95% |
| 2011 FY | 100.78 Million CNY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 307.46 Million CNY | -70.344% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.02 Billion CNY | 74.134% |
| Dirui Industrial Co.,Ltd. | 275.58 Million CNY | -90.044% |
| Medicalsystem Biotechnology Co., Ltd. | 256.55 Million CNY | -104.147% |
| Maccura Biotechnology Co.Ltd | 312.61 Million CNY | -67.534% |
| Guangzhou Wondfo Biotech Co.,Ltd | 487.62 Million CNY | -7.407% |
| Guangdong Hybribio Biotech Co.,Ltd. | 140.47 Million CNY | -272.844% |
| BGI Genomics Co., Ltd. | 92.9 Million CNY | -463.768% |
| Amoy Diagnostics Co., Ltd. | 261.48 Million CNY | -100.296% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | -141.59 Million CNY | 469.897% |